Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Sponsor
Hebei Yanda Hospital
Study ID
NCT02416999
Status
Unknown

Conditions

  • Recurrent High-grade Glioma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.

Key Dates

First listed
Apr 15, 2015
Start date
May 31, 2015
Status verified
Feb 2016
Primary completion
May 31, 2018
Completion
May 31, 2018

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: patient group

Primary Outcome Measure

6-month survival rate of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment [ Time Frame: 6 months ]

Central Contacts